← The Wire
ERASNasdaq
Erasca, Inc.
Pharmaceutical Preparations · DE · CIK 1761918
Erasca develops therapies for RAS/MAPK pathway-driven cancers by targeting key signaling nodes and escape routes
$4.37B
Market cap
$18.29
Last close
+14.2%
1D
+21.3%
5D
8.0M
Volume
Price · last 39 sessions+80.4%
May 4L $9.99 · H $18.29Jun 29
104
Total filings
May 11, 2026
Last filing
12/31
Fiscal year end
10-Q10-QMay 11, 20268-KResults of OperationsMay 11, 2026DEFA14ADEFA14AApr 28, 2026DEF 14ADEF 14AApr 28, 20268-KCompany UpdateApr 27, 20268-KReg FD Disclosure · Company UpdateApr 27, 20268-KCompany UpdateApr 21, 202610-K10-KMar 12, 20268-KResults of OperationsMar 12, 20268-KCompany UpdateJan 29, 20268-KCompany UpdateJan 22, 2026424B5424B5Jan 22, 20268-KResults of OperationsJan 20, 2026424B5424B5Jan 20, 20268-KReg FD Disclosure · Company UpdateJan 12, 202610-Q10-QNov 12, 20258-KResults of OperationsNov 12, 202510-Q10-QAug 12, 20258-KResults of OperationsAug 12, 20258-KShareholder VoteJun 26, 202510-Q10-QMay 13, 20258-KResults of OperationsMay 13, 2025DEFA14ADEFA14AApr 29, 2025DEF 14ADEF 14AApr 29, 202510-K10-KMar 20, 20258-KResults of OperationsMar 20, 20258-KReg FD DisclosureJan 13, 2025SC 13GSC 13GNov 14, 202410-Q10-QNov 12, 20248-KResults of OperationsNov 12, 2024SC 13GSC 13GNov 8, 2024SC 13GSC 13GOct 24, 20248-KCompany UpdateOct 24, 202410-Q10-QAug 12, 20248-KResults of OperationsAug 12, 20248-KShareholder VoteJun 24, 20248-KCompany UpdateJun 24, 2024SC 13GSC 13GMay 31, 2024SC 13GSC 13GMay 29, 2024SC 13GSC 13GMay 28, 2024424B5424B5May 17, 20248-KCompany UpdateMay 17, 20248-KMaterial Agreement · Exit / Disposal CostsMay 16, 202410-Q10-QMay 8, 20248-KResults of OperationsMay 8, 2024DEFA14ADEFA14AApr 26, 2024DEF 14ADEF 14AApr 26, 20248-KMaterial Agreement · Equity IssuanceMar 28, 202410-K10-KMar 27, 20248-KResults of OperationsMar 27, 2024SC 13GSC 13GFeb 14, 20248-KReg FD DisclosureJan 9, 20248-KCompany UpdateDec 11, 20238-KCompany UpdateNov 28, 202310-Q10-QNov 9, 20238-KResults of OperationsNov 9, 20238-KCompany UpdateAug 29, 202310-Q10-QAug 10, 20238-KResults of OperationsAug 10, 20238-KShareholder VoteJun 27, 20238-KCompany UpdateJun 5, 20238-KCompany UpdateMay 25, 202310-Q10-QMay 15, 20238-KResults of OperationsMay 15, 2023DEFA14ADEFA14AApr 28, 2023DEF 14ADEF 14AApr 28, 20238-KCompany UpdateApr 19, 20238-KExecutive ChangeApr 10, 202310-K10-KMar 23, 20238-KResults of OperationsMar 23, 20238-KCompany UpdateFeb 9, 20238-KReg FD DisclosureJan 9, 2023SC 13GSC 13GDec 19, 20228-KEquity Issuance · Company UpdateDec 9, 2022424B5424B5Dec 9, 20228-KMaterial Agreement · Equity IssuanceDec 9, 202210-Q10-QNov 9, 20228-KResults of OperationsNov 9, 20228-KCompany UpdateSep 7, 2022SC 13GSC 13GSep 6, 2022
Insider Activity
In the 90 days to Mar 4, 2026: 2 sold $972K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2026 | Morris ShannonChief Medical Officer | Sell | 20,000 | $15.04 | $301K |
| Jan 7, 2026 | Garner EbunGeneral Counsel & Corp. Sec. | Sell | 120,000 | $5.59 | $671K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance